Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study. - Wikidata - thesis-toulmin - TriplyDB

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

http://www.wikidata.org/entity/Q46585156

about

Combined RNAi-mediated suppression of Rictor and EGFR resulted in complete tumor regression in an orthotopic glioblastoma tumor model Overexpression of s6 kinase 1 in brain tumours is associated with induction of hypoxia-responsive genes and predicts patients' survival Updates of mTOR inhibitors Pushing the envelope in the mTOR pathway: the second generation of inhibitors Next-generation mTOR inhibitors in clinical oncology: how pathway complexity informs therapeutic strategy Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma Targeting the mTOR signaling network for cancer therapy Therapeutic interactions of autophagy with radiation and temozolomide in glioblastoma: evidence and issues to resolve Toward rapamycin analog (rapalog)-based precision cancer therapy Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date Deregulated signaling pathways in glioblastoma multiforme: molecular mechanisms and therapeutic targets Ten things you should know about protein kinases: IUPHAR Review 14 GPCRs in stem cell function PI3K pathway inhibitors for the treatment of brain metastases with a focus on HER2+ breast cancer Will kinase inhibitors make it as glioblastoma drugs?Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?PI3K/PTEN signaling in angiogenesis and tumorigenesis Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma Attributable Risk of Infection to mTOR Inhibitors Everolimus and Temsirolimus in the Treatment of Cancer.A phase II trial of everolimus, temozolomide, and radiotherapy in patients with newly diagnosed glioblastoma: NCCTG N057K Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma.Present and potential future issues in glioblastoma treatment.Identification of hub genes and regulatory factors of glioblastoma multiforme subgroups by RNA-seq data analysis Tuberous sclerosis preclinical studies: timing of treatment, combination of a rapamycin analog (CCI-779) and interferon-gamma, and comparison of rapamycin to CCI-779 Rapamycin delays growth of Wnt-1 tumors in spite of suppression of host immunity.Single cell cytometry of protein function in RNAi treated cells and in native populations Phase II trial of temsirolimus in patients with relapsed or refractory multiple myeloma.Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study.Temsirolimus in combination with carboplatin and paclitaxel in patients with advanced solid tumors: a NCIC-CTG, phase I, open-label dose-escalation study (IND 179).Phase II trial of temsirolimus in children with high-grade glioma, neuroblastoma and rhabdomyosarcoma EORTC 26083 phase I/II trial of dasatinib in combination with CCNU in patients with recurrent glioblastoma.Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02.Therapeutic strategies for inhibiting invasion in glioblastoma.Preclinical therapeutic efficacy of a novel blood-brain barrier-penetrant dual PI3K/mTOR inhibitor with preferential response in PI3K/PTEN mutant glioma.Molecularly targeted therapies for malignant glioma: rationale for combinatorial strategies.The PIK3CA gene as a mutated target for cancer therapy.mTORC1 activation in childhood ependymoma and response to sirolimus.Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma.Personalising pancreas cancer treatment: When tissue is the issue.Glioblastoma: changing expectations?

P2860

Q21133610-53E376BD-C4C1-4DC7-BA46-13164742DF6F Q21296638-4296F6B9-3745-48DF-8C8B-4238791B1D1B Q24607170-5AA5AFFA-E2A8-4FE2-8C2E-95F21CA075CA Q24622222-97EF7BFC-6544-414B-B257-11855152CDF9 Q24628724-95CB768B-73AA-4017-853F-755BDA1A1DBB Q24632791-F083B40F-9BDC-4E70-ADD6-9E068E313233 Q24658334-13A1B3BE-BAB0-4501-91A7-27C1C3A30829 Q26764947-D7BA1B1C-593A-4564-A0AD-A1FAFFBF59FC Q26795606-18593D81-6ADC-4D06-AB47-A4FE689B46A4 Q26822717-55B517E5-42DB-4701-81C4-2EBEB2CC2062 Q26829873-1EEB0DEE-916C-4BA9-90AD-6F97C1815318 Q26849417-61FEB8FF-F013-47C4-A1D3-34ECEA0331CB Q27003270-949E69D6-9835-45D1-943D-4D62F8363E2B Q27006181-B0CE9FA9-1086-42AB-9452-85B04087331B Q27012684-A163F95A-085D-4DDD-B192-74BB34CEEC2D Q28081844-5C3042C6-4C2F-473E-8F33-1766DBBCC9A6 Q28383083-2812AA70-144A-42E1-BE11-7BD6FD61920E Q28472048-803C6245-28B7-48A4-AFA2-E5FA5D316FDD Q30243969-7A2C11CC-0B68-4007-A671-C0B6C12C706B Q30301096-FBEF75AF-4EFC-4ACC-99A6-346E7267AD58 Q30358123-CEED6A60-87C8-4318-BC4D-F7F643F3B42C Q31043603-AEB60983-D992-4001-858A-2DD186A8C9BC Q31125309-80F8403E-2BE4-4CFC-8AB6-900EABD44F3A Q33305157-7EC290A8-A2CD-4AA4-BB55-1F21DDCA4CA2 Q33345588-3A75B184-528A-4351-868A-A0EEC765D07B Q33357070-B4EE936B-F8DB-4A0D-8A7C-4017D7AC1668 Q33383550-A6194CDF-05E5-4596-AB0E-69DF81D50477 Q33383828-8E4A197C-6E7B-4DC5-8F3F-2B0205231EA1 Q33394687-776DC900-C538-4ACF-8719-CB8B46132C09 Q33397833-9CD5A36E-2C13-4706-8A6C-31A8B287969E Q33403967-01D40053-612F-4ECE-9C08-8756A480BAC8 Q33404027-FF6E4277-C6B0-41F3-89F8-2E836F520F41 Q33426563-8464A4AC-1E4C-4059-B2FF-3BEFD7A68942 Q33591658-832FBE62-1F0E-4429-AA15-CE3FAAB989E2 Q33644407-42E3B706-855F-41DC-8F81-7A60CD000844 Q33699378-BC968270-1BFE-4687-80B2-034AEF84ED52 Q33746501-C916C0E0-36E9-4D2E-844E-38AB9F3D8B78 Q33747609-67637D5A-AACC-495C-9B52-9BB333ED75FB Q33801384-68A7FDC2-24F1-4B69-8E89-3BDA6094CBBD Q33873093-79A58B7F-D5A5-4C6A-A0A0-A4930CC2332B

P2860

Phase II trial of temsirolimus (CCI-779) in recurrent glioblastoma multiforme: a North Central Cancer Treatment Group Study.

http://www.wikidata.org/entity/Q46585156

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Phase II trial of temsirolimus ...... Cancer Treatment Group Study.

@en

Phase II trial of temsirolimus

@nl

type

label

Phase II trial of temsirolimus ...... Cancer Treatment Group Study.

@en

Phase II trial of temsirolimus

@nl

prefLabel

Phase II trial of temsirolimus ...... Cancer Treatment Group Study.

@en

Phase II trial of temsirolimus

@nl

P1433

Q46585156-ECE7690B-81C7-4FDE-B564-A596FF2B696F

P1476

Q46585156-87B7B026-C9CC-41DE-8491-DD19BD8309CD

P2093

Q46585156-0DEAF278-C62A-4C57-AEA2-2FE037964B96

Q46585156-11C262AB-A1FA-4CC8-BE41-22191F12EAD1

Q46585156-28CEE1AF-9E78-490F-AF61-E675ACE76243

Q46585156-2C975B6E-F18F-4711-A208-3B8C34DEF8CD

Q46585156-3D49E2FC-8558-4B01-9F9D-1D51932532FB

Q46585156-437BCB72-3F99-47C8-B2CD-B041DDD35F3E

Q46585156-4418675B-89CB-46C3-81A4-91AA61123F9E

Q46585156-542DEC26-7837-4624-B8BC-4F68464E3D4A

Q46585156-7CAEC762-28B4-426B-94A9-F1204C9DC938

Q46585156-906FD30C-E70B-4DBA-8F60-8A0EBF03D6E2

P304

Q46585156-9969786E-0BF2-478D-979D-0440EB90FC4A

P31

Q46585156-76E07DD5-FCE9-479D-AA2D-B5AC78BB83CB

P356

Q46585156-2466563A-3213-44C2-9761-4C9EBA6D297C

P407

Q46585156-28FF5928-ADE0-4A62-91F5-20E7236B6885

P433

Q46585156-166C56FE-324C-42D1-B5C4-8F32F978495C

P478

Q46585156-78C88B1B-3084-42CE-9A16-754569858EE4

P50

Q46585156-692FABD0-A5F7-4A5B-884D-7C3A3714E749

Q46585156-F91EDA1B-1B52-4B62-B3D1-F3C8BCE8EC97

P577

Q46585156-BEFADE6D-82B1-40AC-8720-DAEDCF4BC84F

P698

Q46585156-080A0C70-C716-4187-A861-739CDD25C500

P921

Q46585156-4D83A20C-C60D-4C6F-AA3A-FC404B20F6D2

P356

JCO.2005.23.622

P1433

Journal of Clinical Oncology

P1476

Phase II trial of temsirolimus ...... Cancer Treatment Group Study.

@en

P2093

Bernd W Scheithauer

http://www.w3.org/2001/XMLSchema#string

Daniel J Walsh

http://www.w3.org/2001/XMLSchema#string

J Boni

http://www.w3.org/2001/XMLSchema#string

Jan C Buckner

http://www.w3.org/2001/XMLSchema#string

Janet Dancey

http://www.w3.org/2001/XMLSchema#string

Jeffrey I Kreisberg

http://www.w3.org/2001/XMLSchema#string

Josep M Peralba

http://www.w3.org/2001/XMLSchema#string

Karla Ballman

http://www.w3.org/2001/XMLSchema#string

Kurt A Jaeckle

http://www.w3.org/2001/XMLSchema#string

Matthew J Maurer

http://www.w3.org/2001/XMLSchema#string

P304

5294-5304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1200/JCO.2005.23.622

http://www.w3.org/2001/XMLSchema#string

P407

P433

23

http://www.w3.org/2001/XMLSchema#string

P478

23

http://www.w3.org/2001/XMLSchema#string

P50

Evanthia Galanis

P577

2005-07-05T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15998902

http://www.w3.org/2001/XMLSchema#string

P921

phase II clinical trial